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CASE STUDY Open Access
Orienting patients to greater opioid safety:
models of community pharmacy-based naloxone
Traci C. Green1,2,3,7*, Emily F Dauria3, Jeffrey Bratberg4, Corey S. Davis5 and Alexander Y Walley6
Abstract
The leading cause of adult injury death in the USA is drug overdose, the majority of which involves prescription
opioid medications. Outside of the USA, deaths by drug overdose are also on the rise, and overdose is a leading
cause of death for drug users. Reducing overdose risk while maintaining access to prescription opioids when
medically indicated requires careful consideration of how opioids are prescribed and dispensed, how patients use
them, how they interact with other medications, and how they are safely stored. Pharmacists, highly trained
professionals expert at detecting and managing medication errors and drug-drug interactions, safe dispensing, and
patient counseling, are an under-utilized asset in addressing overdose in the US and globally. Pharmacies provide a
high-yield setting where patient and caregiver customers can access naloxone—an opioid antagonist that reverses
opioid overdose—and overdose prevention counseling. This case study briefly describes and provides two US
state-specific examples of innovative policy models of pharmacy-based naloxone, implemented to reduce overdose
events and improve opioid safety: Collaborative Pharmacy Practice Agreements and Pharmacy Standing Orders.
Background
For thousands of years, pharmacies have served as a
source of preventative and palliative medications—in-
cluding antidotes to poisons—with pharmacists as the
compounder and educator for these preparations [1].
Pharmacists are consistently ranked as one of the most
trusted professions by consumers, viewed as both honest
and ethical [2]. This perception is likely partly a result of
their principled and important contributions to public
health, such as offering vaccinations, selling sterile syrin-
ges, stocking emergency contraception, and refusing to
sell tobacco products. Based on their specialized training
and the role community pharmacies play in the United
States (US) and global health systems, pharmacists are
particularly well positioned to increase opioid safety,
counsel patients, caregivers, and customers about over-
dose risk reduction, and provide naloxone rescue kits to
the community. Despite these strengths, pharmacists are
under-utilized within efforts to address the opioid crisis
currently affecting the US.
Life expectancy in the US is among the shortest of all
high-income countries, driven by high rates of mortality
in people under 50 years of age, who are dying at unpre-
cedented rates of unintentional drug overdose [3]. Drug
overdose deaths have increased nearly sixfold since
1980, making it the leading cause of adult injury death
in the US, surpassing deaths from motor vehicle crashes
[4]. Opioids are the most common drugs involved in
overdose deaths, with the majority being prescription
opioid medications [5]. The US Centers for Disease
Control and Prevention (CDC) have declared the
current conditions an “epidemic” of overdose [6].
Outside of the US, overdose mortality trends in the
European Union countries show persistently high and, in
some countries, increasing rates of fatal overdose [7].
The World Health Organization reports that overdose is
a leading cause of death among people who inject drugs
[8]. Opioids are a cornerstone of modern medicine, pro-
viding critical relief for individuals suffering acute and
some chronic pain conditions, thus full restriction of
these drugs is impossible, impractical, and inhumane. To
live more safely with access to opioid medications re-
quires a more careful consideration of mechanisms for
medical systems to more safely furnish opioids and for
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patients to use them while protecting themselves and
their families from adverse events like over-sedation and
overdose.
Medical experts first called for the provision of nalox-
one outside of the medical setting in the early 1990s [9].
By the mid-1990s, naloxone was being distributed to
heroin users in Italy [10], Germany, and the UK [11,12].
The first programs to dispense naloxone in the US to
people who use drugs began in the late 1990s and early
2000s, beginning in Chicago [13], then San Francisco
[14]. By the mid 2000s, community-based programs in
several US states (e.g., New Mexico, Massachusetts
(MA), and New York) had begun distributing naloxone
and overdose prevention and response training to people
who use drugs and bystanders likely to witness an
overdose [15]. As of June 2014, 644 community-based
overdose education and naloxone distribution (OEND)
programs were in operation in the US, and participants
reported reversing more than 26,463 overdose events
[16]. With 152,283 doses of naloxone dispensed since
1996, community-based programs were the cornerstone
of OEND. As occurred during the 1990s with syringe ac-
cess in the US [17], this paper considers models for
expanding naloxone as one of several harm reduction
supplies provided in the pharmacy setting.
The US pharmacy possesses several unique traits. US
pharmacies are often found in highly visible, highly ac-
cessible locations, as both freestanding independently
owned or chain drug stores, and integrated into
department stores and supermarkets. Many offer the
convenience of extended hours of pharmacy and store
operations. Different from pharmacies in other coun-
tries [18], US pharmacies often sell an extensive range
of retail items beyond prescription and over the counter
medications, from milk and snacks to stationery, house-
hold goods, and seasonal items. Motivating this iteration
of the modern US pharmacy are a focus on accessibility of
commonly used household and personal products for pur-
chase (whether visiting a pharmacy for a prescription or
not) and the convenient placement of non-prescription
items for purchase while awaiting a prescription to be
filled. This environment serves people across varying so-
cioeconomic strata, as one report showed that the equiva-
lent of the entire US population visits pharmacies each
week [19]. With respect to treatments for substance use
disorders, although buprenorphine-based medications are
dispensed there, traditionally, modern US pharmacies do
not dispense methadone or heroin, do not observe dosing
of therapies, and do not administer medications (except
for vaccines). In contrast, many community pharmacies in
Europe and Australia are woven into the fabric of harm
reduction and medical services, and have fewer limits on
medication dispensing paradigms [20,21]. Naloxone ap-
pears to be an exception to this supply pattern, as
naloxone access is generally limited to health profes-
sionals, and in many countries [22] and is of limited avail-
ability in medical settings such as emergency medical
service providers [23]. Uniquely, Scotland has made na-
loxone available in pharmacies without prescription [24],
and Australia is considering a similar status (i.e.,
pharmacist only medication). For this paper, we focus
on the role that pharmacies and pharmacists can po-
tentially play in expanding access to the overdose anti-
dote naloxone in the US.
Optimizing the pharmacist’s accessible, pivotal, and
trusted position in the community is an under-utilized
strategy to promote broader public health goals and re-
duce health disparities [25]. In the context of overdose
prevention, a key component of this strategy is to more
directly involve pharmacists in the provision of overdose
prevention information and services, including expand-
ing provision of the medication naloxone.
Pharmacists can detect medication prescribing errors
and unintended interactions, and regularly interface with
system tools designed to detect inappropriate prescribing
such as prescription-monitoring programs (PMPs),
which, in the US, are state-run electronic databases con-
taining records of medications with abuse potential that
are prescribed to the patient. Unfortunately, in many
cases, the actions available to pharmacists, when a PMP
query indicates a possible heightened risk of overdose,
are limited [26]. Our previous qualitative work with
pharmacists and people who inject drugs in Rhode Is-
land (RI) suggests the following potential strategy for
pharmacists to reduce fatal overdose risk: pharmacy-
based naloxone (PBN) distribution [27]. We found that
pharmacy-based interventions are feasible, desirable, and
accessible to people who are at risk for overdose [27,28].
Pharmacists expressed interest in overdose prevention
interventions, especially those that provide an opportun-
ity to promote safe opioid use among illicit users, reduce
risks of nonmedical opioid use for patients, respect the
time constraints and limited space in most pharmacies,
and capitalize on pharmacist’s professional and patient-
oriented skills. A recent study of pharmacists in San
Francisco concurred [29].
Naloxone, a prescription medication, reverses opioid-
induced respiratory depression (the severe forms of
which are termed “overdose”). It takes effect within mi-
nutes with a half life of 45–70 min, although these
values differ with route of administration, the opioid
consumed, and patient characteristics [30]. Naloxone is
not a controlled substance (i.e., it has no potential for
abuse and thus is not scheduled under US or inter-
national law) and has been used by medical personnel in
the US for more than 40 years as the standard treatment
for opioid overdose [31]. During the past decade, a num-
ber of initiatives have been undertaken to expand
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community access to naloxone, mainly by distributing
naloxone rescue kits to people at an increased risk of
overdose as well as members of their social network
[32]. Kits typically contain two doses of the medication,
instructions on use, and often, other safety materials
such as a face shield for rescue breathing, alcohol swabs,
and rubber gloves. These efforts were initially concen-
trated within needle and syringe access programs and
other harm reduction service providers, and although
they are increasingly supported by public health agencies
and community-based organizations, they frequently
operate outside of mainstream healthcare systems
[15,16]. While initial reviews of these programs are
positive [33–35], access to them is inadequate to reach
people at risk of overdose who do not live in locations
with harm reduction services, or who may be uncom-
fortable seeking these services.
The past five years have seen a dramatic upswing in ef-
forts to expand access to naloxone in the US [16]. In-
creased naloxone access is now championed by a large
number of mainstream organizations including the
American Medical Association [36], the Office of Na-
tional Drug Control Policy [37], and the World Health
Organization [22]. One of the largest barriers to ex-
panded naloxone access is the medication’s prescription
status, which can only be changed by the Food and Drug
Administration (FDA). Consequently, many of the recent
efforts have involved changes to state law to permit na-
loxone to be distributed outside of the traditional
prescriber-patient relationship. To date, over half of the
US and the District of Columbia have modified state law
to increase access to naloxone [38].
These legislative changes all have the goal of increas-
ing naloxone access; however, they vary somewhat by
state. As of June 2015, 32 states have passed laws per-
mitting prescribers to write naloxone prescriptions for
people other than the person at risk of overdose (i.e.,
“carers”, or friends and family members of those at high
overdose risk). Additionally, 21 states have passed legis-
lation allowing “standing” or non-patient-specific nalox-
one prescriptions, which permit naloxone dispensing to
anyone who meets specified criteria (e.g., at risk of ex-
periencing or witnessing overdose). Nearly all of these
laws provide civil immunity for the prescriber, and 26
extend limited immunity from criminal prosecution for
a person who reports an overdose in good faith [39].
Numerous states have also taken steps to equip police
officers and other first responders with naloxone [40,41].
More recently, legal changes focus on mechanisms to
directly involve pharmacies and pharmacists in broader
naloxone access. While moving naloxone to over the
counter status might improve access to the medication,
the FDA has shown little interest in pursuing that path
to date [42]. Instead, states have innovated Collaborative
Pharmacy Practice Agreements, Pharmacy Standing Or-
ders, Naloxone Provision Per Protocol, and Pharmacist
as Prescriber mechanisms, which effectively place nalox-
one “behind the pharmacy counter”. To put PBN in con-
text, Table 1 overviews the naloxone distribution models
observed in the US to date. Models include OEND via
community-based organizations [16], via traditional pre-
scription (from a prescriber-pharmacist dyad), and via
PBN. US communities may employ one or more models
to augment naloxone distribution, depending on the
local epidemiology of opioid overdose, political will, and
legal barriers, among other factors. Based on our experi-
ence as the first state-wide PBN program, we briefly
describe and provide state-specific examples of the fol-
lowing two innovative policy models of PBN, imple-
mented to reduce overdose events and improve opioid
safety: Collaborative Pharmacy Practice Agreements and
Pharmacy Standing Orders.
Case description
Rhode Island: collaborative pharmacy practice agreement
for naloxone
As part of a growing trend in pharmacy practice, collab-
orative pharmacy practice agreements (CPAs) have been
implemented for a range of health conditions with pub-
lic health impact, including vaccinations, Lyme disease
prophylaxis, and diabetes management [43]. CPAs per-
mit a pharmacist to work in collaboration with a pre-
scriber for the purpose of drug therapy management of
patients, pursuant to an authorized and agreed upon
protocol. According to the American Pharmacists Asso-
ciation (APhA), 48 states permit pharmacists to enter
into CPAs with prescribers to manage patient pharma-
ceutical care, and at least 21 states permit pharmacists
to initiate medication therapy under such agreements
[44]. These agreements can generally be used to provide
naloxone to individuals who may be able to use it to save
lives, even without legislative change.
Driving the involvement of pharmacists in the RI over-
dose epidemic was a clear public health need; since
2005, drug overdose deaths in the state outnumbered
deaths from motor vehicle crashes, falls, firearms, and
fire among adults under 85 years of age [45]. The vast
majority of these overdose deaths involve prescription
opioid medications. RI has the nation’s highest rate of
illicit drug use per capita (15.6 % past month use, among
those 12 and older, versus 8.9 % nationally) [46], and
nonmedical use of prescription opioids ranks above the
national average (5.18 % past month use, among those
12 and older, versus 4.57 % nationally) [47,48]. To ad-
dress these stark statistics, the RI Board of Pharmacy
approved a CPA for naloxone (CPAN), which began in
2011, initially as a pilot in five Walgreens Pharmacies
in locations with high prescription opioid overdose
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mortality. The CPAN expanded to all Walgreens Phar-
macies and any other interested pharmacies (e.g.,
CVSHealth), in response to an outbreak of synthetic
fentanyl overdose deaths in Spring 2013, and was for-
malized in regulation in 2014 [49,50]. The Office of Na-
tional Drug Control Policy has recognized the RI
CPAN as a leading public health-commercial collabor-
ation, and an important distribution model for nalox-
one to address overdose risk in the community [51].
When signed by any number of participating pharma-
cists and a single prescriber, the CPAN facilitates
pharmacist-initiated prescription and provision of na-
loxone to eligible patients (Table 2).
Per Pharmacy Board regulations, participating patients
must consent for the exchange of information between
pharmacist and prescriber, complete a brief enrollment
form, and receive a handout with overdose education
and medication specifications, then check-in with the
pharmacist, who verifies their understanding of naloxone
use before it is dispensed. Figure 1 depicts the process
and interactions that broadly define provider-based na-
loxone access (i.e., outside of the community-based
organization setting), beginning with when a patient
approaches a provider for the medication, to naloxone
receipt, and finally to documentation of medication
provision. Involvement in the CPAN requires one hour
of continuing professional education annually to sustain
participation in the agreement, such as the “Prescribe to
Table 2 Eligibility criteria for patient participation in the Rhode
Island collaborative practice agreement for naloxone (CPAN)
▪ Voluntarily request
▪ Recipient of emergency medical care for acute opioid poisoning
▪ Suspected illicit or nonmedical opioid user
▪ High dose opioid prescription (>100 morphine mg equivalents daily)
▪ Methadone prescription to opioid naïve patient
▪ Dispensed an opioid prescription and:
▪ History of smoking
▪ COPD
▪ Respiratory illness or obstruction
▪ Renal dysfunction or hepatic disease
▪ Known or suspected concurrent alcohol abuse
▪ Concurrent benzodiazepine prescription
▪ Concurrent SSRI or TCA anti-depressant prescription
▪ Recently released prisoners from a correctional facility
▪ Released from opioid detoxification or mandatory abstinence program
▪ Patients entering a methadone maintenance treatment program
▪ Patients that may have difficulty accessing emergency medical services
SOURCE: Rhode Island Board of Pharmacy, 2011
Table 1 Naloxone distribution models in the USA: prescription specifications, targeted at-risk populations, and geographic reach
Community-based
organization Naloxone
distribution
Traditional
prescription
Pharmacy-based Naloxone models
CPA Standing
medication order
Protocol order Pharmacist
prescribing
Who issues
prescription?
Prescriber via standing
order
Prescriber Non-pharmacist
prescriber
Non-pharmacist
prescriber
Licensing board Pharmacist
Medical
professionals
required
Varies by state:
prescriber, state/local
health department
Prescriber +
pharmacist
Prescriber +
pharmacist
Prescriber +
pharmacist
Pharmacist Pharmacist
Potential
recipients
Individuals served by the
community-based
organization
Patients of the
prescriber
Varies by state Anyone meeting
criteria specified by
prescriber
Anyone meeting
criteria specified by
licensing board
Anyone for whom
medication is
indicated
Target
overdose risk
population
served
People who use drugs
(prescription opioids,
heroin) who access the
community-based
organization*
People who
use drugs who
are in
treatment/visit
a prescriber*
People who use
drugs (prescription
opioids, heroin) who
visit a pharmacy*
People who use
drugs (prescription
opioids, heroin) who
visit a pharmacy*
People who use
drugs (prescription
opioids, heroin) who
visit a pharmacy*
People who use
drugs (prescription
opioids, heroin) who
visit a pharmacy*
Patients
prescribed
opioids who
are at risk of
overdose*
Patients filling a
prescription for
opioids at a
pharmacy who are
at risk of overdose*
Patients filling a
prescription for
opioids at a
pharmacy who are
at risk of overdose*
Patients filling a
prescription for
opioids at a
pharmacy who are
at risk of overdose*
Patients filling a
prescription for
opioids at a
pharmacy who are
at risk of overdose*
Geographic
reach
Limited to where
community-based orga-
nizations are located and
operate
Limited to
where the
prescriber
practices
Any participating
pharmacy within the
state
Any participating
pharmacy within the
state
Any participating
pharmacy within the
state
Limited to where
the pharmacist
practices
*A majority of states now permit prescriptions to be written for third parties (e.g., friends, staff of organizations that provide services to individuals at risk of
overdose) as well as the person at risk of overdose
CPA collaborative practice agreement
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Prevent” online training for prescribers and pharmacists
at opioidprescribing.com. The University of Rhode
Island (URI) also developed an online continuing edu-
cation program for pharmacists to receive the standard
1-h PBN training required to initiate their participation.
As of June 2015, 363 pharmacists had completed the
URI training, 96 % of whom were employed by retail
chain pharmacies. During 2014, through the CPAN, RI
roughly doubled the community-based distribution of
naloxone. From January 2014 to May 2015, 572 PBN
prescriptions were dispensed (Figure 2), comprising
25 % of all naloxone distributed in RI. While health
departments of many neighboring states are reporting
increases in overdose deaths from 2013 onward (New
Figure 1 Pharmacy Naloxone Access Models. Process flow as experienced by patient and pharmacist. Nlx Naloxone, Rx prescription, MD medical
doctor, DO doctor of osteopathic medicine, NP nurse practitioner, PA physician assistant, CPA collaborative practice agreement, State abbreviations: WA
Washington, RI Rhode Island, VA Virginia, GA Georgia, CA California, NV Nevada, NM New Mexico, ID Idaho
Figure 2 Overdose deaths and pharmacy-based naloxone prescriptions dispensed in Rhode Island, 2009 to 2015, by quarter. SOURCE: Rhode
Island Department of Health, 2015
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Hampshire, 2013 = 193 deaths, 2014 = 321 deaths [52];
Connecticut, 2013 = 490 deaths, 2014 = 558 deaths [53];
Massachusetts, 2013 = 967 deaths, 2014 = 1008 deaths
projected [54]), RI experienced only seven more deaths
in 2014 (n = 239) than in 2013 (n = 232) [55]. Other
interventions to reduce overdose in RI were intro-
duced contemporaneously (i.e., equipping law enforce-
ment with naloxone, emergency department-based
naloxone distribution), so causal attribution of the
attenuation to PBN alone is not possible. Efforts to
further expand PBN access will be evaluated beyond
this proximal impact.
Massachusetts: pharmacy standing order
More than 8926 people died of opioid overdoses in MA
between 2000 and 2014 [54], mirroring national trends
of increasing opioid overdose deaths. Different from
most other states, however, MA has a well-established,
community naloxone distribution network [35] that has
operated since 2006. Under this model, the medical dir-
ector (AYW) serves as the single prescriber to all
community-based naloxone recipients. While this com-
munity network remains essential, it is not able to meet
the growing need for naloxone. In March 2014, the Gov-
ernor declared a public health emergency, and, in re-
sponse, the MA Board of Registration in the Pharmacy
and the Drug Control Program adopted regulations one
month later that authorized pharmacists to dispense na-
loxone under a standing order signed by a physician
[56]. In July 2014, a law went into effect that essentially
mirrored the existing Order [57]. These steps were ne-
cessary in MA to accomplish broader “behind the phar-
macy counter” access to naloxone, because existing
CPA regulations only permit pharmacists to dispense
medication to individuals that are established patients
of the prescriber.
Pharmacy standing orders are similar to those in exist-
ence in many states for expedited partner treatment of
sexually transmitted infections, which allows a pharma-
cist to dispense antibiotics to the partner of a person
with a sexually transmitted infection without examining
the partner. Figure 1 depicts the patient and pharmacist
flow of interactions under a pharmacy standing order. In
this way, PBN offers additional outlets, with immense
geographic reach, to locales that may have less commu-
nity naloxone distribution coverage and/or with elevated
mortality risk.
The pharmacy standing order is conceptually similar
to the CPA in terms of implementation and intended
reach (Table 1), and that of MA includes many elements
of the RI CPAN; the standing order must be signed by a
physician and the pharmacy manager at each outlet;
copies must be filed with the Board of Registration in
Pharmacy and maintained onsite at the pharmacy;
pharmacists need to have an understanding of the ap-
propriate function and use of naloxone; counseling of
the customer by the pharmacist; inclusion of an over-
dose prevention information sheet within the naloxone
prescription; and labeling of the naloxone prescription
with an expiration date. Who is eligible to receive na-
loxone under pharmacy standing orders is left up to the
physician and pharmacist to determine in the agree-
ment (Table 1). An August 2012 law explicitly permits
prescribing both to people at risk of opioid overdose
and people likely to be opioid overdose bystanders, thus
the patient eligibility specified on the pharmacy stand-
ing orders typically includes both of these groups
[58,59]. Between March and December 2014, 145 indi-
vidual retail pharmacies within MA, primarily in com-
munities with high rates of overdose mortality, filed a
naloxone pharmacy standing order with the Board of
Registration in Pharmacy. It will be some time before
PBN meets or exceeds the high distribution volume of
the community-based programs, but collaborations
such as those between drug treatment programs and
community pharmacies in many of the pharmacy loca-
tions with standing orders suggest that there are mul-
tiple local implementation prospects in high-overdose
burden communities.
Discussion
Here, we briefly outlined two models of PBN and pro-
vided state-specific examples that are immediately
implementable within existing regulatory frameworks of
many US states, and may serve as models in inter-
national settings. Indeed, the CPAN and pharmacy
standing order are conceptually similar to other legal
frameworks, such as national patient group directions
[60], which serve as a structure for wider scale PBN in
the UK [61]. Pharmacy-based naloxone is one public
health intervention that better leverages pharmacies’ cap-
acity and pharmacists’ skills. By utilizing well-established
health systems, where appointments are not required, ser-
vices are provided at low or no-cost, and trusted health
professionals are accessible, PBN expands the reach of
naloxone to individuals beyond those currently being
served by community-based and harm reduction organi-
zations. While implementation is early and more compre-
hensive evaluations are in order, PBN is being dispensed
to patients and caregivers.
An important element of the described PBN models is
a clear path for prescription drug reimbursement on
public and private payer formularies, in addition to a
consultation fee, similar to that paid for immunization
administration. Currently, most major public and private
insurers cover naloxone formulations; however, this re-
imbursement does not include a pharmacist’s consult-
ation with the patient. The mass vaccination campaign
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of the 2009 H1N1 influenza vaccine may serve as a use-
ful model for developing policies and/or executive orders
that require health insurance coverage to include PBN
naloxone and administrative fees. In order to extend the
reach of the campaign, the federal government covered
the cost of the vaccine itself and required that any provider
agreeing to administer the vaccination should not charge
an administrative fee that exceeded the region Medicare or
Medicaid rate [62]. This reimbursement coverage extended
to vaccinations provided in traditional (e.g., doctor’s offices,
health care facilities) and non-traditional settings (e.g., phar-
macies), and served as incentive for US pharmacies to
adopt immunization administration.
In addition to reimbursement challenges, several bar-
riers may limit the wide scale implementation of PBN.
These barriers include access to formulation and prod-
ucts; legal misconceptions about naloxone prescription,
dispensing and use; the need for education and advocacy
at the patient-, familial-, social network-, and health care
provider-levels (e.g., pharmacists, physicians, pharmacy,
and medical schools and associations); and ethical con-
siderations (i.e., pharmacists refusing naloxone to certain
patients), among others [27,63–65]. Many of these chal-
lenges are not unique to the pharmacy, but rather, are
shared by naloxone distribution models across out-
patient and community settings. Future evaluations of
PBN should assess for the presence of these and new
challenges, to understand their impact and to measure
the contribution of PBN to mortality reduction.
The two state examples differed considerably in their
base rates of community naloxone availability, permit-
ting different potential contributions of PBN to the risk
environment. In RI, the limited competing community
sources for naloxone meant that PBN was central to
state-wide distribution efforts with greater geographic
reach, whereas in MA, the pharmacies with standing or-
ders provide additional outlets in communities with
existing harm reduction support infrastructure and high-
overdose burden. Some states may prioritize reaching
certain high-risk populations through PBN. While every
person who receives an opioid prescription is a potential
candidate for PBN, special attention could be directed to
those known to be at increased risk of opioid overdose
and adverse events (Table 2), in a pharmacist-initiated
rather than a patient-initiated PBN approach. Strategies
for improved implementation and for maximizing PBN’s
reach are ripe areas of research.
Recently, APhA and the National Association of Boards
of Pharmacy formally recognized the role of the pharma-
cist in overdose recognition, education, and furnishing na-
loxone [66,67] The evolving role of pharmacies in this
area suggests a number of approaches beyond PBN for
directly or indirectly addressing the opioid epidemic, in-
cluding: 1) pharmacy-prescriber partnerships to better
manage opioid medications, reduce overprescribing, and
increase access to addiction care; 2) counseling about and
supplying patients with safe storage tools [68,69]; and 3)
increasing community access to treatment of opioid-
use disorders with evidence-based medicines (i.e., in-
pharmacy buprenorphine prescribing, and daily dis-
pensing of methadone or buprenorphine in areas with
inadequate access to licensed opioid treatment pro-
grams, and in-pharmacy naltrexone injections), as is
common in many international settings [21,70].
Conclusions
PBN, exemplified by state models described in RI and
MA, can be adopted and applied elsewhere nationally
and internationally as a feasible mechanism for ex-
panded access to naloxone. PBN may provide a pivotal
foundation and catalyst for pharmacy-based services
from which pharmacists can have more central roles as
facilitators and advocates for treatment and recovery.
For example, in several countries including Australia,
Scotland, Germany, and Canada [20,21,71,72], commu-
nity pharmacies are a major point (and in some local-
ities, the only point) [21] of effective treatment of
opioid-use disorders; co-locating naloxone access along-
side such provision is consistent with pharmacy harm
reduction service delivery, and generally supportive at-
titudes of pharmacists toward harm reduction [70], as
several communities in Scotland have accomplished
[73]. With an unprecedented number of opioid over-
doses globally [22], an expanding pool of opioid use ini-
tiates in the US [74], and an aging baby boomer
generation with high lifetime drug use and high bur-
dens of chronic pain often treated with opioids [75,76],
it is imperative that creative, sustainable solutions, such
as PBN, are implemented.
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